No Matches Found


Loading...
{{stock_short.stock.stock_name.value}}
{{stock_short.stock.price.value}}
{{stock_short.stock.price_difference.value}} ({{stock_short.stock.price_percentage.value}}%)
{{ra.field}}
{{ra.stock_return.chgp}}%
{{ra.sensex_return.chgp}}%
{{stock_short.result_details[0].header}}
{{stock_short.result_details[0].latest.to_period}}
{{stock_short.result_details[0].latest.from_period}}
Change%
{{latest.field}}
{{latest.to}}{{latest.value_suffix}}
{{latest.from}}{{latest.value_suffix}}
{{latest.per}}
Figures in Rs cr

4D Molecular Therapeutics Hits New 52-Week High of $13.32

4D Molecular Therapeutics, Inc. has achieved a new 52-week high, recovering significantly from its previous low. However, the company's one-year performance remains negative, contrasting with broader market gains. With a market capitalization of USD 476 million, it continues to face challenges, including losses and a lack of dividends.

Jun 30 2026 05:09 PM IST
share
Share Via
4D Molecular Therapeutics Hits New 52-Week High of $13.32

Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

As of August 25, 2025, 4D Molecular Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and On-Balance Volume, while year-to-date performance outpaces the S&P 500 at 27.47%.

Sep 20 2025 07:55 PM IST
share
Share Via

Is 4D Molecular Therapeutics, Inc. overvalued or undervalued?

As of February 28, 2025, 4D Molecular Therapeutics, Inc. is assessed as overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, poor stock performance, and significant contrasts with peers.

Jun 25 2025 09:08 AM IST
share
Share Via

Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

As of June 17, 2025, the technical trend has shifted to mildly bearish, driven by daily moving averages and monthly MACD indicators, despite some weekly bullish signals.

Jun 25 2025 08:55 AM IST
share
Share Via

What does 4D Molecular Therapeutics, Inc. do?

4D Molecular Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 and a net loss of $48 million as of March 2025. The company has a market cap of $192.25 million and key metrics indicate it is currently loss-making with no dividend yield.

Jun 22 2025 06:52 PM IST
share
Share Via

How big is 4D Molecular Therapeutics, Inc.?

As of Jun 18, 4D Molecular Therapeutics, Inc. has a market capitalization of 192.25 million, with net sales of 0.02 million and a net profit of -176.43 million over the latest four quarters. The company has shareholder's funds of 510.61 million and total assets of 560.38 million as of Dec 24.

Jun 22 2025 06:07 PM IST
share
Share Via

{{list.post_title}}

{{list.post_excerpt}}

{{list.post_date_sep}}
share
Share Via
{{list.post_title_sep}}

{{list.post_title}}

{{list.post_excerpt}}

{{list.post_date_sep}}
share
Share Via

Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read